Filing Details

 

---

---

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D/A

 

Under the Securities Exchange Act of 1934

(Amendment No. 22)*

 

OPKO Health, Inc.

(Name of Issuer)

 

Common Stock, par value $0.01 per share

(Title of Class of Securities)

 

68375N103

(CUSIP Number)

 

Camielle Green Associate General Counsel, Secretary OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 Telephone: (305) 575-4100

(Name, address and telephone number of person authorized to receive notices and communications)

 

 

January 18, 2024

(Date of event which requires filing of this statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box  ☐.

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

 

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

---

---

 

 

CUSIP No. 68375N103

Schedule 13D

PAGE 2 of 7

 

 

1		NAME OF REPORTING PERSONS   Frost Gamma Investments Trust
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (a)  ☒        (b)  ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS   WC,OO
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION   Florida

	7		SOLE VOTING POWER
NUMBER OF			205,868,225	Shares
SHARES BENEFICIALLY	8		SHARED VOTING POWER
OWNED BY			-
EACH REPORTING PERSON	9		SOLE DISPOSITIVE POWER
WITH			205,868,225	Shares
	10		SHARED DISPOSITIVE POWER
			-

11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
		205,868,225	Shares
12		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) ☐
13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
		28.7%(1)
14		TYPE OF REPORTING PERSON   OO

 

(1)	Calculated based on (i) 718,136,502 shares outstanding as of January 18, 2024, as communicated by the Issuer to the Reporting Person.

 

 

CUSIP No. 68375N103

Schedule 13D

PAGE 3 of 7

 

 

1		NAME OF REPORTING PERSONS   Frost Nevada Investments Trust
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (a)  ☒        (b)  ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS   WC, OO
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION   Florida

	7		SOLE VOTING POWER
NUMBER OF			30,127,177	Shares
SHARES BENEFICIALLY	8		SHARED VOTING POWER
OWNED BY			-
EACH REPORTING PERSON	9		SOLE DISPOSITIVE POWER
WITH			30,127,177	Shares
	10		SHARED DISPOSITIVE POWER
			-

11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
		30,127,177	Shares
12		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) ☐
13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
		4.2%(1)
14		TYPE OF REPORTING PERSON   OO

 

(1)	Calculated based on 718,136,502 shares outstanding as of January 18, 2024, as communicated by the Issuer to the Reporting Person.

 

 

CUSIP No. 68375N103

Schedule 13D

PAGE 4 of 7

 

 

1		NAME OF REPORTING PERSONS   Phillip Frost, M.D.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (a)  ☒        (b)  ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS   N/A
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION   United States

	7		SOLE VOTING POWER
NUMBER OF			241,851,853	Shares
SHARES BENEFICIALLY	8		SHARED VOTING POWER
OWNED BY			2,851,830	Shares
EACH REPORTING PERSON	9		SOLE DISPOSITIVE POWER
WITH			241,851,853	Shares
	10		SHARED DISPOSITIVE POWER
			2,851,830	Shares

11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
		244,703,683	Shares(1)
12		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) ☐
13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
		33.9%(2)
14		TYPE OF REPORTING PERSON IN

 

(1)

Includes (i) 3,068,951 shares of Common Stock held individually by Dr. Frost; (ii) 30,127,177 shares of Common Stock held by the Frost Nevada Investments Trust, which is controlled by Dr. Frost as sole trustee; (iii) options to acquire 2,787,500 shares of Common Stock, which are exercisable within 60 days; (iv) 205,868,225 shares of Common Stock held by the Gamma Trust, which is controlled by Dr. Frost as sole trustee; and (v) 2,851,830 shares of Common Stock held by the Phillip and Patricia Frost Philanthropic Foundation, Inc., which is controlled by Dr. Frost and his wife.

 

(2)	Calculated based on (i) 718,136,502 shares outstanding as of January 18, 2024, as communicated by the Issuer to the Reporting Person; and (ii) options to acquire 2,787,500 shares of Common Stock, which are exercisable within 60 days.

 

 

CUSIP No. 68375N103

Schedule 13D

PAGE 5 of 7

 

 

EXPLANATORY NOTE

 

This Amendment No. 22 (the “Amendment”) amends and supplements the statement on Schedule 13D filed on February 15, 2007, as amended by Amendment No. 1 to the Schedule 13D filed on April 6, 2007, as amended by Amendment No. 2 to the Schedule 13D filed on August 2, 2007, as amended by Amendment No. 3 to the Schedule 13D filed on February 14, 2008, as amended by Amendment No. 4 to Schedule 13D filed on August 21, 2008, as amended by Amendment No. 5 to the Schedule 13D filed on February 26, 2009, as amended by Amendment No. 6 to the Schedule 13D filed on March 19, 2009, as amended by Amendment No. 7 to the Schedule 13D filed on October 1, 2009, as amended by Amendment No. 8 to the Schedule 13D filed on March 28, 2011, as amended by Amendment No. 9 to the Schedule 13D filed on October 24, 2011, as amended by Amendment No. 10 to the Schedule 13D filed on October 11, 2012, as amended by Amendment No. 11 to the Schedule 13D filed on March 21, 2013, as amended by Amendment No. 12 to the Schedule 13D filed on September 16, 2013, as amended by Amendment No. 13 to the Schedule 13D filed on February 17, 2015, as amended by Amendment No. 14 to the Schedule 13D filed on December 18, 2015, as amended by Amendment No. 15 to Schedule 13-D filed on September 20, 2017, as amended by Amendment No. 16 to Schedule 13-D filed on November 20, 2018, as amended by Amendment No. 17 to Schedule 13-D filed on March 20, 2019, as amended by Amendment No. 18 to Schedule 13-D filed on March 22, 2019, as amended by Amendment No. 19 to Schedule 13-D filed on November 1, 2019, as amended by Amendment No. 20 to Schedule 13-D filed on August 19, 2022, as amended by Amendment No. 21 to Schedule 13-D filed on February 21, 2023 (collectively, the “Original Schedule 13D”), by The Frost Group, LLC (the “Frost Group”), a previously reporting entity, Frost Gamma Investments Trust (“Gamma Trust”), Frost Nevada Investments Trust (“Frost Nevada”), and Phillip Frost, M.D. (“Dr. Frost”). This Amendment is filed pursuant to the Joint Filing Agreement as executed by the reporting persons listed on the cover pages to this Amendment. The Joint Filing Agreement, filed as Exhibit 1 to Amendment No. 15 to the Schedule 13D filed on September 20, 2017, is hereby incorporated by this reference.

 

This Amendment is filed with respect to the common stock, par value $0.01 per share (“Common Stock”), of OPKO Health, Inc., a Delaware corporation (the “Issuer”).

 

ITEM 3.

Source and Amount of Funds or Other Consideration. Item 3 is amended by adding the following paragraph to the end of the item:

 

In January 2024, the Issuer completed a private offering of $230.0 million aggregate principal amount of our 3.75% Convertible Senior Notes due 2029 (the “144A Notes”).  Additionally, the Issuer issued and sold approximately $71.1 million aggregate principal amount of its 3.75% Convertible Senior Notes due 2029 (the “Affiliate Notes” and, together with the 144A Notes, the “Notes”) pursuant to the terms of a note purchase agreement entered into on January 4, 2024 (the “Affiliate Note Purchase Agreement”) by and among the Issuer and certain investors including, Gamma Trust (the “Affiliate Purchasers”). Pursuant to the Affiliate Note Purchase Agreement, the Issuer issued and sold the Affiliate Notes to the Affiliate Purchasers in exchange for $55.0 million aggregate principal amount of the Issuer’s existing 5% convertible promissory notes (the Amended Notes), together with approximately $16.1 million of accrued but unpaid interest thereon, held by the Affiliate Purchasers.  Holders may not convert their notes prior to the close of business on the business day immediately preceding September 15, 2028, unless certain circumstances exist. The conversion rate is initially equal to 869.5652 shares of common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $1.15 per share of common stock).  No additional consideration was provided by Gamma Trust.

 

ITEM 4.

Purpose of Transaction. Item 4 is amended by adding the following paragraph to the end of the item:

 

On or about January 4, 2024 the Issuer issued the Affiliate Notes.  The Affiliate Notes may not be converted prior to the close of business on the business day immediately preceding September 15, 2028, unless certain circumstances exist.

 

ITEM 5.

Interest in Securities of the Issuer. Item 5 is deleted in its entirety and replaced with the following text:

 

(a)-(b) Gamma Trust directly beneficially owns 205,868,225 shares of Common Stock. The 205,868,225 total shares of Common Stock beneficially owned by Gamma Trust constitute approximately 28.7% of the Issuer’s outstanding shares of Common Stock, based upon (i) 718,136,502 shares of Common Stock outstanding as of January 18, 2024 as communicated by the Issuer to the Reporting Person. Dr. Frost is the sole trustee of Gamma Trust and holds sole voting and dispositive power with respect to 205,868,225 shares of Common Stock.

 

 

CUSIP No. 68375N103

Schedule 13D

PAGE 6 of 7

 

 

Frost Nevada directly beneficially owns 30,127,177 shares of Common Stock. The 30,127,177 total shares of Common Stock beneficially owned by Frost Nevada constitute approximately 4.2% of the Issuer’s outstanding shares of Common Stock, based upon 718,136,502 shares of Common Stock outstanding as of January 18, 2024 as communicated by the Issuer to the Reporting Person. Dr. Frost is the sole trustee of Frost Nevada and holds sole voting and dispositive power with respect to 30,127,177 shares of Common Stock.

 

Dr. Frost, as the sole trustee of Gamma Trust, may be deemed to beneficially own the 205,868,225 shares of Common Stock beneficially owned by Gamma Trust. Dr. Frost, as the sole trustee of Frost Nevada may be deemed to beneficially own the 30,127,177 shares of Common Stock beneficially owned by Frost Nevada. In addition, the Phillip and Patricia Frost Philanthropic Foundation, Inc., which is controlled by Dr. Frost and his wife, owns 2,851,830 shares of Common Stock. Dr. Frost individually owns 3,068,951 shares of Common Stock and options to acquire 2,787,500 shares of Common Stock, which are exercisable within 60 days, and has sole voting and dispositive power over each. The 244,703,683 shares of Common Stock beneficially owned by Dr. Frost constitute approximately 33.9% of the Issuer’s outstanding shares of Common Stock, based upon (i) 718,136,502 shares of Common Stock outstanding as of  January 18, 2024 as communicated by the Issuer to the Reporting Person; and (ii) options to acquire 2,787,500 shares of Common Stock, which are exercisable within 60 days. Dr. Frost, as sole trustee of Gamma Trust, has sole voting and dispositive power over 205,868,225 shares of Common Stock. Dr. Frost, as sole trustee of Frost Nevada, has sole voting and dispositive power over 30,127,177 shares of Common Stock. Dr. Frost has shared voting and dispositive power with respect to 2,851,830 shares of Common Stock owned by the Phillip and Patricia Frost Philanthropic Foundation, Inc.

 

(c) In the last 60 days prior to the filing of this Amendment No. 22, Frost Nevada and Dr. Frost have not effected any transactions in the shares of Common Stock.

 

In the last 60 days prior to the filing of this Amendment No. 22, Gamma Trust acquired a total of 3,911,531 shares of Common Stock on the open market at prices ranging from $0.853 to $0.9985 per share for an aggregate purchase price of approximately $3,654,120.67. The following table sets forth the information with regard to Common Stock purchased by Gamma Trust on the open market in the last 60 days.

 

Date		Shares of Common Stock				Aggregate Purchase Price				Weighted Average Price Per Share
January 5, 2024			1,500,000			$	1,344,548.69			$	0.8964
January 11, 2024			511,531			$	480,380.55			$	0.9391
January 16, 2024			1,000,000			$	954,337.77			$	0.9543
January 18, 2024			400,000			$	386,212.23			$	0.9655
January 19, 2024			500,000			$	488,641.43			$	0.9985

 

(d) Except as described herein, no other person is known by any Reporting Person to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of the Issuer beneficially owned by them.

 

 

CUSIP No. 68375N103

Schedule 13D

PAGE 7 of 7

 

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

					Frost Gamma Investments Trust
Dated:	January 22, 2024				By:		/s/ Phillip Frost, M.D.
					Name:		Phillip Frost, M.D.
					Title:		Sole Trustee
					Frost Nevada Investments Trust
Dated:	January 22, 2024				By:		/s/ Phillip Frost, M.D.
					Name:		Phillip Frost, M.D.
					Title:		Sole Trustee
Dated:	January 22, 2024				By:		/s/ Phillip Frost, M.D.
					Name:		Phillip Frost, M.D.
					Title:		Phillip Frost, M.D., Individually